Piper Sandler lowered the firm’s price target on NeoGenomics (NEO) to $11 from $12 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- Watch Out! Analysts Have Recently Downgraded These Stocks
- NeoGenomics Faces Revenue Guidance Cut and Growth Challenges, Analyst Maintains Hold Rating
- NeoGenomics Earnings Call: Growth Amid Challenges
- Peloton upgraded, Booking downgraded: Wall Street’s top analyst calls
- NeoGenomics price target lowered to $8 from $10 at Morgan Stanley